Since its founding in 2017, Ciliatech has attracted significant corporate and public support, enabling its founders to create a fundamental shift in an operational procedure that:
Having successfully demonstrated proof of concept, Ciliatech is currently preparing the CID implant for CE marking.
Glaucoma is one of the leading causes of blindness for people over the age of 60. The effect of glaucoma can be so gradual that a change in vision may be unnoticeable, until the condition reaches an advanced stage.
While the surgical approach, trabeculectomy, remains the ‘Gold Standard’, it is a more than 50-year-old technique. Although it significantly reduces IOP below 15 mmHg, it also generates numerous medical complications that are quite often critical.
Today, technological evolutions in materials and design, and our greater understanding of pathological and physiological environments, demand a more advanced approach, similar to the level of progress that has been made in treating cataracts.
Ciliatech has created this higher level of performance in glaucoma surgery by developing a new class of implant that addresses the increasing need to treat this disease, which, globally, affects 80M people per year; durably and with very minimal adverse effects.